Kyverna Therapeutics, Inc.

About Kyverna Therapeutics, Inc.

Kyverna Therapeutics is a clinical-stage cell-therapy company developing engineered Treg and CAR-T cell treatments for autoimmune diseases. It combines synthetic biology with cellular engineering to create next-generation regulatory T cells that selectively suppress pathologic immune activity. Its lead candidate, KYV-101, is an autologous CD19 CAR-Treg therapy in Phase 1/2 trials for lupus nephritis and systemic sclerosis. Headquartered in Emeryville, California, Kyverna operates a cGMP manufacturing facility and is advancing a pipeline of programmable cell therapies aimed at resetting immune tolerance in chronic inflammatory disorders.